Drawing for SPHEROTEC

USPTO serial 79067099

SPHEROTEC

Reviewed by CopyMark Law Group

Reg. 4434280Status 404
Filing date
Status date
Registration date
Nov 19, 2013
Examiner
MITTLER, KEVIN A
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with SPHEROTEC?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Jeffrey A. Smith

JEFFREY A SMITH MILLEN WHITE ZELANO & BRANIGAN PC2200 CLARENDON BLVDSUITE 1400ARLINGTON, VA 22201-3360

Goods and services

ClassDescriptionStatusFirst use
001Scaffold-free and solid phase free chemical and chemical preparations used in tissue and cell-based spheroid cultures for scientific purposes; chemical preparations, namely, collections of biological tissues and cells for scientific purposes; tissue in the nature of biological tissue, namely, blood, stem cells, tumour cells, fibroblasts, foam cells, glial cells, adipocytes, benign and malignant primary cells, hybridomas, antibody producing cells; arrays of biological cells, namely, cancer cells, benign cells, stem cells, tumour cells, fibroblasts, foam cells, glial cells, adipocytes, benign and malignant primary cells, hybridomas, antibody producing cells; fixed arrays of biological cells, namely, cancer cells, benign cells, stem cells, tumour cells, fibroblasts, foam cells, glial cells, adipocytes, benign and malignant primary cells, hybridomas, antibody producing cells; biological cells prepared into a format for scientific purposes and research for scientific research use; cell culture systems, three-dimensional cell culture system comprising cell clusters and aggregates for scientific research useSECTION 70 - CANCELLED—
005Scaffold-free or solid phase free pharmaceutical and veterinary preparations used in tissue and cell-based spheroid cultures for the diagnosis and treatment of cancer; collection of biological tissue and cells, namely, surgical tissues and cells intended for the generation of cell clusters and cell aggregates for medical purposes; tissue, namely, surgical tissues, for diagnosis and treatment of cancer and for medical purposes; fibroblasts, foam cells, glial cells, stem cells, adipocytes, benign and malignant primary cells, hybridomas, antibody producing cells for the generation of cell clusters or cell aggregatesSECTION 70 - CANCELLED—
035Compilation and management of computerized databases used for tissue and cell-based spheroid culturesSECTION 70 - CANCELLED—
042Scientific and technological services and research and design in the field of integrated system architecture that allows for the rapid development of highly interactive and customizable learning applications; computer diagnostic services; diagnostic testing of humans for medical research purposes; medical research services; medical research in the field of oncology; medical research in the field of disease indications and identification of tumor indications; testing of drugs, biological and chemical preparations for medical research purposes; pharmaceutical research, inspection and development; pharmaceutical drug development services; medical and scientific research, namely, conducting clinical trials concerning biological and chemical preparations and pharmaceuticals; medical and scientific research, namely, researching profiles of biological and chemical preparations, pharmaceuticals, antigens; testing for scientific and medical research purposes of combinations of biological and chemical preparations and pharmaceuticals; testing for medical research purposes to determine the chemo-resistance and chemo-sensitivity of biological and chemical preparations and pharmaceuticals; medical research in the nature of testing the efficacy and toxicity of biological and chemical preparations and pharmaceuticals; medical research in the nature of testing the effects of biological and chemical preparations and pharmaceuticals on cell toxicity levels; medical research in the nature of pharmacokinetic testing of biological and chemical substances and known pharmaceuticals; medical research concerning the absorption, delivery, metabolism, excretion and toxicity testing of biological and chemical preparations and pharmaceuticals ; medical and scientific research in the field of pharmaceuticals, genetic changes induced by biological or chemical preparations or pharmaceuticals, and pharmaceutical dosing levels; research and development of pharmaceutical treatment therapies for others; scientific research concerning tumour biology, progression and metastasis; medical research concerning optimal treatment and therapy regimes for individuals; medical research concerning optimal cancer therapy for individuals; research and development of new products for others in relation to prediction of cancer therapy; scientific and medical research in the field of radiotherapy; research, development and design of new radiotherapy products for others; scientific and medical research in the field of radiochemotherapy; research, development and design of new products for others in the field of radiochemotherapy; scientific and medical research in the field of stem cells and biomarker discovery, characterization and development; medical research in the fields of ex-vivo therapies, patient material profiling, tumor profiling, in vitro modeling of tissue and biological systems, cell culture systems, three-dimensional cell culture systems, and three-dimensional culture of donor and patient cells; laboratory research services, namely, isolation, culture and treatment of donor and patient tissues and cells for medical research purposes; research laboratory services, namely, preparation of cell lines, primary tissues and fluids, and biological material into a format for scientific and medical research purposes; medical research concerning immunohistology, immunohistology preparation and investigation;Opposition No. 912064346research laboratory services, namely, creation and preparation of biological material into or onto a format for immunohistology investigation, creation and preparation of biological material on a solid or wax support, preparation of sections or slices of biological material on to slides, all for medical research purposes; medical research concerning small molecule development, preparation and generation, antibody research, development, preparation and generation, and vaccine research, development, preparation and generation; provision of information and data relating to scientific and technological research and development; provision of information and data relating to medical and veterinary research and development; provision of information and data relating to scientific and medical research concerning pharmaceuticals, drug testing, drug discovery and development, and testing of biological material; all of the aforementioned services relating to or using tissue and cell-based spheroids culturesSECTION 70 - CANCELLED—
044Medical and veterinary services; medical diagnostic testing services; medical diagnostic testing services of humans; medical diagnostic and clinical testing services; medical and clinical oncology diagnostic testing services for humans; medical diagnostic testing services in the field of oncology; performing diagnosis of disease indications, performing diagnosis of tumour disease indications; medical screening services for drugs, biological and chemical entities and potential and known pharmaceuticals; medical services, namely, medical testing for and identifying antigens and providing drug therapy for inhibiting antigens; providing individualizing cancer therapy services; providing medical diagnostic services for cancer therapy; medical services, namely, personalized cancer therapy; medical services, namely, radiotherapy; medical services, namely, radiochemotherapy; medical services, namely, preparations of ex-vivo therapies; all relating to medical and veterinary fields; all of the aforementioned services relating to or using tissue and cell-based spheroids culturesSECTION 70 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
May 24, 2019DENCNOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED—
May 24, 2019DETHDEATH OF INTERNATIONAL REGISTRATION—
Nov 19, 2018REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Mar 6, 2014FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Feb 19, 2014FICSFINAL DISPOSITION NOTICE SENT TO IB—
Feb 19, 2014FIMPFINAL DISPOSITION PROCESSED—
Feb 19, 2014FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Nov 19, 2013R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Oct 16, 2013TMBNTTAB RELEASE CASE TO TRADEMARKS—
Oct 16, 2013OP.TOPPOSITION TERMINATED NO. 999999—
Oct 16, 2013OP.DOPPOSITION DISMISSED NO. 999999—
Sep 23, 2013MAILPAPER RECEIVED—
Feb 8, 2013DOCKASSIGNED TO EXAMINER—
Sep 8, 2012RFNPREFUSAL PROCESSED BY IB—
Aug 7, 2012OP.IOPPOSITION INSTITUTED NO. 999999—
Aug 6, 2012OPNSOPPOSITION NOTICE (IB REFUSAL) SENT TO IB—
Aug 4, 2012OPNCOPPOSITION NOTICE (IB REFUSAL) CREATED—
Feb 23, 2012ETOFEXTENSION OF TIME TO OPPOSE RECEIVED—
Feb 7, 2012PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 3, 2012OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Jan 26, 2012TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jan 18, 2012OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Jan 18, 2012OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Jan 18, 2012NPUBNOTICE OF PUBLICATION—
Jan 3, 2012CNEAEXAMINERS AMENDMENT MAILED—
Dec 31, 2011PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Dec 30, 2011CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Dec 30, 2011XAECEXAMINER'S AMENDMENT ENTERED—
Dec 30, 2011CNEAEXAMINERS AMENDMENT -WRITTEN—
Dec 30, 2011ZZZXPREVIOUS ALLOWANCE COUNT WITHDRAWN—
Nov 22, 2011CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Oct 18, 2011RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Apr 18, 2011RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Oct 18, 2010RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Oct 9, 2010OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Sep 23, 2010OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Sep 23, 2010OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Apr 16, 2010RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Apr 16, 2010ALIEASSIGNED TO LIE—
Oct 16, 2009CNSLLETTER OF SUSPENSION MAILED—
Oct 15, 2009CNSLSUSPENSION LETTER WRITTEN—
Sep 28, 2009TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 28, 2009CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 28, 2009ALIEASSIGNED TO LIE—
Sep 24, 2009TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 23, 2009ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 23, 2009REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jun 5, 2009RFNTREFUSAL PROCESSED BY IB—
May 11, 2009RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
May 11, 2009RFRRREFUSAL PROCESSED BY MPU—
May 9, 2009RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
May 8, 2009CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 28, 2009MAFRAPPLICATION FILING RECEIPT MAILED—
Apr 24, 2009DOCKASSIGNED TO EXAMINER—
Apr 24, 2009NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 23, 2009REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance